Talis Biomedical Corporation

Talis Bio reported Q2 revenue of $0.5 million, driven mostly by NIH grant income. Total operating expenses were $17 million, down from $28 million in the same period last year; R&D expense was $11 million versus $17 million, and SG&A was $6 million versus $9 million. The company did not provide EPS or gross margin figures. Unrestricted cash and cash equivalents were $98 million at June 30, 2023, and management said net cash used in operating activities improved 53% year over year, with average monthly cash burn within its target range of $4 million to $5 million. For the COVID-19 study, management said enrollment targets are 50 positives and 500 negatives, the study is about two-thirds complete, and submission is expected in very early 2024 after analysis and reporting. The company reiterated its goal of securing three cleared panels by the end of 2025, with HSV as a possible upside beyond that timeline.

Rob Kelley framed the quarter as a step forward on multiple strategic fronts: advancing a disciplined regulatory plan, generating early data for differentiated women's and sexual health tests, and improving manufacturing readiness. He emphasized that the company is prioritizing panels that Ob/Gyn and other providers want at the point of care, and said the COVID-19 study supports the instrument clearance foundation for future submissions. His tone was confident but measured, repeatedly tying execution to a goal of three cleared panels by the end of 2025.

Becky Markovich highlighted a much lower cost structure in Q2, with operating expenses of $17 million versus $28 million last year, including R&D of $11 million and SG&A of $6 million. She said cash and cash equivalents were $98 million, the company has no debt, and first-half 2023 operating cash use improved 53% year over year. She also pointed to operational savings from moving into a smaller Redwood City office and lab, which cut the footprint by two-thirds and is expected to save about $9 million over the life of the lease, while reiterating that current cash should fund operations into 2025.

Analysts focused on timing and sequencing of regulatory milestones, asking about the COVID-19 study size, submission timing, and whether the company could commercialize panels soon after clearance. Management said the COVID study began in June, is two-thirds enrolled, and that a submission in very early 2024 is the best expectation, with clearance timing dependent on FDA review. They also clarified the order of priorities: COVID-19 instrument clearance first, then the fluid panel and CLIA waiver, then CT/NG/TV, while HSV remains in feasibility and pre-submission work is expected before year-end.